Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen.
Saved in:
| Title: | Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. |
|---|---|
| Authors: | Tu, Ya‐Ping1 (AUTHOR) yaping.tu@gmail.com, Lagraauw, H. Maxime2 (AUTHOR), Method, Michael3 (AUTHOR), Wang, Yuemei4 (AUTHOR), Hanze, Eva2 (AUTHOR), Li, Lingling4 (AUTHOR), Parrott, Timothy5 (AUTHOR), Sloss, Callum M.6 (AUTHOR), Westin, Eric H.3 (AUTHOR) |
| Source: | British Journal of Clinical Pharmacology. Jan2025, Vol. 91 Issue 1, p220-231. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 03065251 |
|---|---|
| DOI: | 10.1111/bcp.16250 |
